

Original Research

Diabetes and Tuberculosis – Tackling Double Trouble

Gyanshankar P. Mishra¹, Radha P. Munje², Madhav B. Dawkore³

¹ Associate Professor, Dept. of Respiratory Medicine, Indira Gandhi Government Medical College, Nagpur

² Professor & Head, Dept. of Respiratory Medicine, Indira Gandhi Government Medical College, Nagpur

³ Junior Resident, Dept. of Respiratory Medicine, Indira Gandhi Government Medical College, Nagpur

Corresponding author: Dr. Gyanshankar P. Mishra , Associate Professor, Dept. of Respiratory Medicine, Indira Gandhi Government Medical College, C.A. Road, Nagpur, Maharashtra, India- 440018

Abstract:

Introduction: Diabetes mellitus (DM) is an important and recognized risk factor for tuberculosis (TB). India is a high TB burden country along with an increased prevalence of diabetes in its population. The current study aimed to study the diagnostic profile and treatment outcomes of tuberculosis in diabetics (TBDM) as compared to that in non-diabetics.

Materials and methods: A retrospective analysis from clinical records of TB patients diagnosed between November 2016 to April 2018 (eighteen months) was carried out in a tertiary care teaching institute.

Results: Out of a total 1592 TB patients diagnosed during the study period, 66 (4.15 %) patients were diabetics. Amongst them, 49 patients had declared outcomes and were analyzed further. 98 TB patients without diabetes, diagnosed during the same period, were selected randomly in 1:2 ratio as the control group. There were 26(53%) microbiologically confirmed TB patients and 23(47%) clinically diagnosed TB cases among diabetics as compared to 43(43.87%) microbiologically confirmed TB patients and 55(56.12%) clinically diagnosed TB cases among non-diabetics. There were 41(83.63%) pulmonary and 8(16.32%) extra-pulmonary TB cases among diabetics as compared to 56 (57.14%) pulmonary and 41(42.85%) extra-pulmonary TB cases among non-diabetics. Among diabetics, 39 (79.59%) patients were newly diagnosed and 10(20.40%) patients were retreatment cases of TB whereas 80(81.63 %) patients were newly diagnosed and 18(18.36 %) patients were retreatment cases of TB among non-diabetics. Poor treatment outcome of TB was seen in 14 (28.57%) diabetics as compared to 10(10.2%) non-diabetics.

Discussion: Diabetics are at an increased risk of developing pulmonary TB. TB is associated with poor treatment outcome in diabetics.

Conclusion: A robust screening of diabetics for TB is imperative and the healthcare provider must be well aware of the diagnostic spectrum and possible poor treatment outcomes of TB in these patients.

Keywords: Diabetes, Tuberculosis, TB, India, Anti TB Treatment

Introduction:

Diabetes mellitus (DM) is an important and recognized risk factor for tuberculosis (TB). Diabetes triples a person's risk of developing TB.(1) TB can temporarily cause impaired glucose tolerance which is a risk factor for developing diabetes as well as the presence of diabetes can cause increase in blood sugar levels, and persistent hyperglycemic levels can have a negative impact on presentation and outcome of TB.(2) India is a high TB burden country along with an increased prevalence of diabetes in its population and hence the association of both these diseases needs to be addressed.(3)

Objectives:

The study aimed to evaluate the following parameters: 1. Proportion of microbiologically confirmed and clinically diagnosed cases of TB in diabetics. 2. Proportion of pulmonary and extra-pulmonary TB in diabetics. 3. Proportion of newly diagnosed and retreatment cases of TB in diabetics. 4. Treatment outcome of TB among diabetics as compared to non-diabetics.

Materials and Methods:

A retrospective analysis from clinical records of TB patients diagnosed between November 2016 to April 2018 (eighteen months) was carried out in the department of Respiratory medicine, Indira Gandhi Government Medical College, Nagpur. The study would comprise of two groups viz. Diabetics with TB and Non-diabetics with TB as control group, with patients in both groups in the ratio of 1:2. The various comparative parameters would then be analysed in both groups.

Results:

Out of a total 1592 TB patients diagnosed during the study period, 66 (4.15 %) patients were diabetics. Amongst them, 49 patients had declared outcomes and were analyzed further. 98 TB patients without diabetes, diagnosed during the same period, were selected randomly in 1:2 ratio as the control group. The results are depicted in Table no 1.

The significant findings were as follows: The proportion of pulmonary TB was more in diabetics as compared to non-diabetics (83.63% vs 57.14%; $p = 0.0017$). Tuberculosis had increased proportion of poor treatment outcomes (Loss to follow up, failure, drug resistance & death) in diabetics as compared to non-diabetics (Figure no. 1) (28.56% vs 10.2%; $p = 0.0045$). There was no significant difference in proportion of microbiologically confirmed and clinically diagnosed cases of TB in diabetics as compared to non-diabetics. There was no significant difference in proportion of newly diagnosed and retreatment cases of TB in diabetics as compared to non-diabetics.

Table no. 1 Various Result Parameters in TB patients with Diabetes as compared to TB patients without Diabetes

Variables	TB with DM (N=49)	TB without DM (n=98)	OR (95%CI)	p value
Male	32(65.30)	51(52.04)		
Female	17(34.69)	47(47.95)	1.73	0.126
Diagnosis of TB Cases				
Microbiologically confirmed	26(53)	43(43.87)	1.44	0.2929
Clinically Diagnosed	23(47)	55(56.12)		
Type of TB cases				
New	39(79.59)	80(81.63)	0.875	0.13

Retreatment	10(20.40)	18(18.36)		
Pulmonary TB	41(83.63)	56(57.14)		
Extra-pulmonary TB	8(16.32)	42(42.85)	3.75	0.0017**
Treatment Outcomes				
<i>Successful outcomes</i>	35(71.42)	88(89.79)		
Cured	25(51.02)	36(36.73)		
Treatment completed	10(20.40)	52(53.06)		
<i>Poor Outcomes</i>	14(28.56)	10(10.2)	8.06	0.0045**
Lost to follow up	7(14.28)			
Failure		5(5.10)		
Died	4(8.16)	4(4.08)		
Shifted to regime for MDR TB	3(6.12)	1(1.02)		




Figure 1. Treatment outcomes of Tuberculosis in Diabetics and Non- Diabetics.

Discussion:

Our study shows that TB is associated with relatively poor outcome in diabetics in accordance with the previous studies (Dooley et al. (2009), Sulaiman et al (2013), Pan et al (2015), Siddiqui et al. (2016) and Workneh et al (2016)).(3–7) The possible reasons for this could be as following: **a. Poor glycaemic control:** Optimal glycaemic control might improve tuberculosis treatment outcomes and prevent many of the diabetes associated complications.

However, tuberculosis often leads to loss of appetite, bodyweight, and physical activity, all of which might have a cumulative adverse effect on glucose homeostasis. (2,8) b. Subtherapeutic levels of anti TB drugs in diabetics. Previous studies have shown that people with diabetes have lower plasma concentrations of rifampicin, isoniazid and rifampicin than expected (2,9,10) c. High mycobacterial burden at treatment initiation: It has been shown previously that TB patients with DM tend to have a higher mycobacterial burden at start of treatment as compared to patients without DM, possibly due to immune dysregulation.(11) In the current study also the proportion of microbiologically confirmed TB cases were higher among diabetics as compared to non-diabetics, though statistically non-significant. d. Drug interactions: Rifampicin interacts with many drugs, reducing plasma concentrations of sulphonylureas, repaglinide and nateglinide, pioglitazone, saxagliptin, linagliptin, canagliflozin, and dapagliflozin. Also, theoretically, dipeptidyl peptidase (DPP) IV inhibitors may cause immune paresis and possibly worsen treatment outcomes in TB management (2,8,12,13) e. ADR's (Adverse Drug Reactions) : It has been previously reported that increased incidence of ADR's to anti TB drugs is seen in diabetics.(3) f. Drug Resistance: A recently published meta-analysis by Liu et al. concluded that DM was an independent risk factor for MDR-TB (Multi drug resistant TB), especially for primary MDR-TB.(14)

Considering the poor treatment outcome of TB in diabetes, it is imperative to screen for TB in diabetics and vice versa. A good initial counselling, active supervision for possible ADR's and early management of the same is important in TB patients with diabetes. Baseline screening for drug resistance is mandatory in these patients. Considering that major proportion of diabetics had pulmonary TB as compared to extrapulmonary TB, it is imperative that all diabetics who are TB suspects should undergo sputum smear and CBNAAT (Cartridge Based Nucleic Acid Amplification Test) examination.

Conclusion:

A robust bidirectional screening i.e. screening of diabetics for TB and vice versa is imperative. The healthcare provider must be well aware of the diagnostic spectrum and possible poor treatment outcomes of TB in these patients.

References:

1. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med [Internet]. 2008 Jul 15 [cited 2018 Oct 2];5(7):e152. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18630984>
2. Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol [Internet]. 2014 Sep [cited 2018 Sep 14];2(9):740–53. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S221385871470110X>
3. Siddiqui AN, Khayyam KU, Sharma M. Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study. Biomed Res Int [Internet]. 2016 Aug 24 [cited 2018 Sep 14];2016:1–11. Available from: <http://www.hindawi.com/journals/bmri/2016/7273935/>

4. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* [Internet]. 2009 Dec [cited 2018 Sep 14];9(12):737–46. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19926034>
5. Sulaiman SAS, Khan AH, Ahmad N, Iqubal MS, Muttalif AR, Hassali MA. Impact of diabetes mellitus on treatment outcomes of tuberculosis patients in tertiary care setup. *Am J Med Sci* [Internet]. 2013 Apr 1 [cited 2018 Oct 2];345(4):321–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23531965>
6. Pan S-C, Ku C-C, Kao D, Ezzati M, Fang C-T, Lin H-H. Effect of diabetes on tuberculosis control in 13 countries with high tuberculosis: a modelling study. *lancet Diabetes Endocrinol* [Internet]. 2015 May 1 [cited 2018 Oct 2];3(5):323–30. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25754415>
7. Workneh MH, Bjune GA, Yimer SA. Diabetes mellitus is associated with increased mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients in South-Eastern Amahra Region, Ethiopia. *Infect Dis poverty* [Internet]. 2016 Mar 21 [cited 2018 Oct 2];5:22. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27009088>
8. Niazi AK, Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control. *J Diabetes Metab Disord* [Internet]. 2012 Dec 20 [cited 2018 Oct 3];11(1):28. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23497638>
9. Ramachandran G, Agibothu Kupparam HK, Vedhachalam C, Thiruvengadam K, Rajagandhi V, Dusthacker A, et al. Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India. *Antimicrob Agents Chemother* [Internet]. 2017 May 1 [cited 2018 Sep 28];61(5):e02464-16. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28242663>
10. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunegoro H, Ascobat P, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. *Antimicrob Agents Chemother* [Internet]. 2013 Aug 1 [cited 2018 Oct 2];57(8):3614–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23689725>
11. Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis. *Immunology* [Internet]. 2017 [cited 2018 Oct 2];152(1):13–24. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28543817>
12. Hillson R. Tuberculosis and diabetes. *Pract Diabetes* [Internet]. 2017 Jun 1 [cited 2018 Sep 28];34(5):149–50. Available from: <http://doi.wiley.com/10.1002/pdi.2106>
13. Yorke E, Atiase Y, Akpalu J, Sarfo-Kantanka O, Boima V, Dey ID. The Bidirectional Relationship between Tuberculosis and Diabetes. *Tuberc Res Treat* [Internet]. 2017 [cited 2018 Sep 28];2017:1–6. Available from: <https://www.hindawi.com/journals/trt/2017/1702578/>
14. Liu Q, Li W, Xue M, Chen Y, Du X, Wang C, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. *Sci Rep* [Internet]. 2017 [cited 2018 Oct 2];7(1):1090. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28439071>